Ülke: İsrail
Dil: İngilizce
Kaynak: Ministry of Health
DICLOFENAC AS POTASSIUM
NOVARTIS ISRAEL LTD
M01AB05
TABLETS
DICLOFENAC AS POTASSIUM 50 MG
PER OS
Required
NOVARTIS SAGLIK, GIDA VE TARIM URUNLERI SAN.VE TIC. A.S., TURKEY
DICLOFENAC
DICLOFENAC
Management of pain and primary dysmenorrhea, when prompt pain relief is desired.
2020-11-30
عم نمازتلاب هلوانت بجي يذلا ةدعملا ةيامحل ً ارخآ ً ءاود بيبطلا فصي نأ زئاجلا نم تنك اذإ وأ ، ً انسم تنك اذإ ،قباسلا يف ةدعملاب لكاشم نم تيساق اذإ ةصاخ ،ءاودلا اذه .كلذل ةفاضلإاب ةنيعم ةيودأ لوانتت ءاودلا لوانت ةيفيكو ىتم .ماعطلا ةبجو دعب وأ ءانثأ ءاودلا لوانت لضف ُ ي .ءام وأ بارش عم هلمكأب صرقلا علب بجي .ةعرسب لمعتل ملافاتاك صارقأ ميمصت مت دقل .رملأا اذه لوح تايطعم دجوت لا ،صرقلا غضم وأ قحس ،رطش زوجي لا ربكأ ً ايئاود ً ارادقم أطخلاب تلوانت اذإ أطخلاب لفط علب اذإ وأ ، ً اطرفم ً ايئاود ً ارادقم أطخلاب ، ً ارخآ ً اصخش وأ تنأ تلوانت اذإ ةبلع رضحأو ىفشتسملا يف ئراوطلا ةفرغ ىلإ وأ بيبطلا ىلإ ً اروف هجوت ،ءاودلا نم .كعم ءاودلا .بيبطلا ةيصوت بسح جلاعلا ىلع ةبظاوملا بجي ءاودلا لوانت تيسن اذإ .كركذت لاح يئاود رادقم لوانت بجي ،ددحملا تقولا يف ءاودلا اذه لوانت تيسن اذإ فعاضم يئاود رادقم لوانت زوجي لاف ،مداقلا يئاودلا رادقملا دعوم ً ابيرقت ناح اذإ نكل تقولا يف يلاتلا يئاودلا رادقملا طقف لوانت .يسنملا يئاودلا رادقملا نع ضيوعتلل صارقأ 3( غلم 150 هردق يئاود رادقم زواجت زوجي لا .بيبطلا رشتسإو يدايتعلإا .ةعاس 24 للاخ )غلم 50 تاذ نسحت أرط ولو ىتح ،بيبطلا ةراشتسإ نودب ءاودلاب جلاعلا نع فقوتلا زوجي لا .ةيحصلا كتلاح ىلع رادقملا نم دكأتلاو ءاودلا عب Belgenin tamamını okuyun
CAT API MAR23 V3 UK SmPC Feb2023 Business Use Only 1. TRADE NAME OF THE MEDICINAL PRODUCT CATAFLAM ® 50 MG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50mg of diclofenac potassium Chemical name: Potassium-[o-[(2, 6-dichlorophenyl)-amino]-phenyl]-acetate Excipient(s) with known effect: Sucrose For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Management of pain and primary dysmenorrhea, when prompt pain relief is desired. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION As a general recommendation, the dose should be individually adjusted. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use). GENERAL TARGET POPULATION The recommended initial daily dose is 100 to 150 mg. In milder cases, 75 to 100 mg daily is usually sufficient. The total daily dose should generally be divided into 2 or 3 separate doses, as applicable. In primary dysmenorrhoea, the daily dose should be individually adjusted and is generally 50 to 150 mg. An initial dose of 50 mg is usually sufficient. If necessary, an initial dose of 100 mg can be prescribed with a maximum of 200 mg/day reached over the course of several menstrual cycles. Treatment should be started on appearance of the first symptoms and, depending on the symptomatology, continued for a few days. In migraine an initial dose of 50 mg should be taken at the first signs of an impending attack. In cases where pain relief within 2 hours after the first dose is not sufficient, a further dose of 50 mg may be taken. If needed, further doses of 50 mg may be taken at intervals of 4-6 hours, not exceeding a total dose of 200 mg per day. SPECIAL POPULATIONS PAEDIATRICS Cataflam ® tablets are not recommended for use in children and adolescents below 14 years of age. For adolescents aged 14 years and over, a daily dose of 75 to 100 mg is usually sufficient. The maximum da Belgenin tamamını okuyun